Popees Baby Care board to meet Oct 24 on preferential issue mods
- Board meeting scheduled for October 24, 2026
- Agenda includes modifying preferential issue proposal
- Proposal involves share swap arrangement for non-cash consideration
- EGM date extension to be approved for shareholder consent
- Trading window remains closed until 48 hours post-results

*this image is generated using AI for illustrative purposes only.
Popees Baby Care India Limited has scheduled a Board of Directors meeting for Saturday, October 24, 2026. The primary agenda is to consider and approve modifications to a previously approved proposal for raising funds through a preferential issue via a share swap arrangement.
The meeting will also address the extension of the date for the Extra-Ordinary General Meeting (EGM). This EGM was convened to seek shareholder approval for the said preferential issue. The company filed this intimation with BSE Limited under Regulations 29 and 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Agenda details
The Board will specifically review the following matters:
- Modification to the fund-raising proposal initially approved by the Board on October 8, 2026.
- The issuance of securities on a preferential basis by way of private placement, pursuant to a Share Swap Arrangement, for consideration other than cash.
- Extension of the EGM date required for shareholder approval of the preferential issue.
Trading window status
In continuation of an earlier intimation dated September 28, 2026, the trading window for dealing in the securities of Popees Baby Care India Limited remains closed. This restriction applies to all designated persons and their immediate relatives. The window will reopen 48 hours after the declaration of the company's financial results.
Historical Stock Returns for Popees Baby Care
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -2.47% |
What specific terms of the share swap arrangement are being modified, and how might these changes affect the valuation of the target entity?
How will the extension of the EGM date impact the overall timeline for completing the preferential issue and subsequent capital infusion?
Which strategic partners or entities are involved in the share swap, and what synergies are expected to arise from this non-cash consideration structure?


































